ArticleNature genetics2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
Article in Nature genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed.
- Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.European journal of nuclear medicine and molecular imaging · 2022Trial
- Copy number alteration burden predicts prostate cancer relapse.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs).Gene · 2026Review
- TRPM8 levels determine tumor vulnerability to channel agonists.Molecular oncology · 2025Article
- XAF1 is secreted from stressed tumor cells to activate T cell-mediated tumor surveillance via Lck-ERK signaling.Neoplasia (New York, N.Y.) · 2025Article
- Metastatic hormone-naïve prostate cancer: a distinct biological entity.Trends in cancer · 2024Review
- Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion.Molecular cancer research : MCR · 2023Article
- Discovery of a highly potent and orally available importin-Acta pharmaceutica Sinica. B · 2023Article
- Ablative radiotherapy improves survival but does not cure autochthonous mouse models of prostate and colorectal cancer.Communications medicine · 2023Article
- IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities.Research and reports in urology · 2023Review
- ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.Frontiers in endocrinology · 2023Article
- Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.Molecular cancer research : MCR · 2022Article
- Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer.Nature cancer · 2022Article
- Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies.Biomolecules · 2022Article
- Article
- Role of ZBTB7A zinc finger in tumorigenesis and metastasis.Molecular biology reports · 2021Review
- MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy.Cancer medicine · 2021Article
- Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Advances in Rodent Models for Breast Cancer Formation, Progression, and Therapeutic Testing.Frontiers in oncology · 2021Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
21 authors.
Funding
Abstract
Here we report an integrated analysis that leverages data from treatment of genetic mouse models of prostate cancer along with clinical data from patients to elucidate new mechanisms of castration resistance. We show that castration counteracts tumor progression in a Pten loss-driven mouse model of prostate cancer through the induction of apoptosis and proliferation block. Conversely, this response is bypassed with deletion of either Trp53 or Zbtb7a together with Pten, leading to the development of castration-resistant prostate cancer (CRPC). Mechanistically, the integrated acquisition of data from mouse models and patients identifies the expression patterns of XAF1, XIAP and SRD5A1 as a predictive and actionable signature for CRPC. Notably, we show that combined inhibition of XIAP, SRD5A1 and AR pathways overcomes castration resistance. Thus, our co-clinical approach facilitates the stratification of patients and the development of tailored and innovative therapeutic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.